The proinflammatory cytokine Tumour Necrosis Factor (TNF)-a is implicated in a variety of skeletal muscle pathologies. Here, we have investigated how in vitro cotreatment of skeletal muscle C2C12 cells with b-agonists modulates the TNF-a-induced inflammatory program. We observed that C2C12 myotubes express functional TNF receptor 1 (TNF-R1) and b2-adrenoreceptors (b2-ARs). TNF-a activated the canonical Nuclear Factor-kB (NF-kB) pathway and Mitogen-Activated Protein Kinases (MAPKs), culminating in potent induction of NF-kB-dependent proinflammatory genes. Cotreatment with the bagonist isoproterenol potentiated the expression of inflammatory mediators, including Interleukin-6 (IL-6) and several chemokines. The enhanced production of chemotactic factors upon TNF-a/isoproterenol cotreatment was also suggested by the results from migrational analysis. Whereas we could not explain our observations by cytoplasmic crosstalk, we found that TNF-R1-and b2-AR-induced signalling cascades cooperate in the nucleus. Using the IL-6 promoter as a model, we demonstrated that TNF-a/isoproterenol cotreatment provoked phosphorylation of histone H3 at serine 10, concomitant with enhanced promoter accessibility and recruitment of the NF-kB p65 subunit, cAMP-response element-binding protein (CREB), CREB-binding protein (CBP) and RNA polymerase II. In summary, we show that b-agonists potentiate TNF-a action, via nuclear crosstalk, that promotes chromatin relaxation at selected gene promoters. Our data warrant further study into the mode of action of b-agonists and urge for caution in their use as therapeutic agents for muscular disorders.
Introduction
Skeletal muscle atrophy is a devastating consequence of a large number of diseases, including cancer and myopathies, but is also apparent in physiological processes, such as aging or disuse. Several lines of evidence indicate that inflammatory factors contribute to the loss of skeletal muscle mass and function [1] . One of the cytokines that has been especially associated with the development of skeletal muscle abnormalities is Tumour Necrosis Factor (TNF)-a and elevated levels of TNF-a are apparent in skeletal muscle wasting disorders [2] . TNF-a transduces its activity via two different types of membrane-bound receptors, namely TNF-receptor 1 (TNF-R1) and TNF-receptor 2 (TNF-R2), which stimulate different cellular processes. TNF-R ligation leads to the recruitment of receptor-specific adaptor proteins, which in turn activate a cascade of protein kinases and several downstream transcription factors, including the Nuclear Factor (NF)-kB [3] .
NF-kB is the generic term for members of a family of ubiquitously expressed transcription factors, that act as homo-or heterodimers to regulate genes involved in immunity and inflammation [4] . In the context of inflammatory gene expression, the p65-p50 NF-kB heterodimer has been most intensively studied. TNF-a induces the canonical NF-kB signalling pathway, marked by activation of the IkB kinase b (IKKb) complex, which phosphorylates the IkBa inhibitor proteins that, in resting cells, sequester NF-kB in the cytoplasm. Phosphorylated IkBa is ubiquitinylated and targeted for proteasomal degradation, allowing NF-kB to migrate from the cytoplasm to the nucleus, where it drives transcription of genes containing NF-kB-responsive elements [4] . Whereas NF-kB function has been mainly studied in immune cells, recent reports have demonstrated a role for NF-kB in a variety of other cell types, including skeletal muscle. For instance, it was shown that interference with NF-kB activity, via overexpression of IkB supersuppressor or p65 knock-out, reduces inflammation and improves the regeneration process in different skeletal muscle disease models [1, 5] .
The adrenergic receptors belong to the family of G-protein coupled receptors (GPCRs) and skeletal muscle cells express mainly the b 2 -adrenoreceptor (b 2 -AR) subtype [6] . b 2 -AR agonists (b-agonists) are well known for their anabolic properties and several in vivo studies support the therapeutic potential of bagonists in skeletal muscle wasting disorders [7] [8] [9] . Interestingly, the existence of extensive crosstalk between b 2 -AR and TNF-R-mediated signalling cascades was documented in different cell types and it was postulated that b-agonists have anti-inflammatory effects, that can be, at least in part, explained by inhibition of NFkB activity [10] [11] [12] . Arguing against the anti-inflammatory effects of b 2 -AR stimulation is the repeated observation, in different model systems, that b-agonists potentiate the expression of the prototypical inflammatory cytokine IL-6, a phenomenon that was also reported in skeletal muscle cells in vivo and in vitro [13, 14] .
Recent genome-wide expression studies have yielded detailed information on the individual effects of TNF-a or b-agonists on the skeletal muscle transcriptome [15, 16] . However, the effect of controlled cotreatment of skeletal muscle cells with TNF-a and bagonists has, to our knowledge, never been investigated. In addition, the molecular basis for the reported selective effect of bagonists on NF-kB dependent gene expression remains to be elucidated. Therefore, we have investigated how b-agonists modulate TNF-a-induced signalling cascades, focusing on the NF-kB pathway and its target genes in C2C12 myotubes. As opposed to previous reports in other cell types, we found no direct inhibitory effects of b-agonists on the NF-kB cascade in C2C12 skeletal muscle cells. Instead, we found that the b-agonist isoproterenol potently enhanced TNF-a-induced expression of selected NF-kB target genes, such as interleukin-6 (IL-6) and chemokine (C-X-C motif) ligand 5 (CXCL5). In addition, we report that this selective potentiation is not mediated by cytoplasmic modulation of NF-kB function, but instead relies on atypical epigenetic events. Finally, in support of the physiological relevance of our findings, the co-activation of b 2 -AR/TNF-Rs in myotubes promoted the migration of undifferentiated myoblasts.
Materials and Methods

Reagents and Antibodies
Isoproterenol and Trichostatin A (TSA) were purchased from Sigma Aldrich (St. Louis, MO, USA) and used at 10 mM and 100 nM, respectively. Murine TNF-a was a gift from the VIB Department for Molecular Biomedical Research of Ghent University (VIB-UGent, Gent, Belgium) and was used at 2000 IU/ml. Insulin-like growth factor-1 (IGF-1) was from ImmunoTools (Friesoythe, Germany) and was used at 10 ng/ml. Anti-b 2 -AR, anti-TNF-R1, anti-myogenin, anti-PARP, anti-P-H3-Ser10, anti-CBP, anti-RNA polymerase II, anti-p65, anti-IkBa, anti-P-CREB-Ser133 and anti-PKAc were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-P-p65-Ser536, anti-P-ERK-Thr202/Tyr204, anti-P-JNK-Thr183/Tyr185, anti-Pp38-Thr180/Tyr182, anti-P-MSK-1-Thr581, anti-Lamin A/C and anti-CREB were from Cell Signaling Technology (Danvers, MA, USA). Anti-Ac-H3-Lys27 and GAPDH were from AbCam (Cambridge, UK). Anti-a-tubulin and anti-a-actin were from Sigma-Aldrich. In figures, the expression ''antibody anti-'' was substituted by the Greek letter ''a-''. AatII and HincII restriction enzymes were obtained from New England BioLabs (Ipswich, MA, USA).
Cell culture
Murine C2C12 cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Gibco by Life Technologies) supplemented with 10% foetal bovine serum (Gibco by Invitrogen, Paisley, UK), 100 IU/ml penicillin and streptomycin (Gibco by Life Technologies, Grand Island, NY, USA) (referred to herein after as growth medium or GM). Cells were cultured in an incubator at 37uC in a humidified atmosphere containing 5% CO 2 . Cells were passaged using 0.05% Trypsin+EDTA (Gibco by Life Technologies). In experiments using myoblasts, cells were seeded at 200000 cells/ well in a 6-well format and GM was substituted by starvation medium (DMEM containing 1% foetal bovine serum, 100 IU/mL penicillin and streptomycin, referred as SM) for 24 hours. In experiments using myotubes, cells were seeded at 300000 cells/ well in a 6-well format and GM was substituted by differentiation medium to induce differentiation (DMEM containing 2% horse serum, 100 U/ml penicillin and streptomycin, referred as differentiation medium or DM). To obtain myotubes, cells were cultured for 5 days in DM.
RNA isolation, cDNA synthesis and Real-Time Quantitative PCR (RT-qPCR)
Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Venlo, Netherlands). Reverse transcription was performed on 0.5 mg of total mRNA using the PrimeScript RT reagent kit from Takara Bio Inc. (Shiga, Japan). For real time cDNA amplification we used the Roche SYBR Green Mastermix (Roche Applied Science, Penzberg, Germany) and primers listed in Table S1 . Fluorescence was monitored using the Light Cycler 480II (Roche). A serial dilution of a representative cDNA sample was used to generate a standard curve and determine the efficiency of the PCR reaction for all primer sets which was used in the subsequent calculation of relative mRNA inputs. Expression of each gene was normalized to expression of the HPRT house-keeping gene and results are presented as fold induction compared to untreated cells. For clarity the Y-axis is interrupted in some cases.
Luciferase reporter assay
The NF-kB-luciferase reporter plasmid and the b-galactosidase control constructs have been described elsewhere [17] . The CREluciferase reporter plasmid was from Stratagene (LaJolla, CA). Transient transfection was performed using the Neon Transfection system (Invitrogen), according to the manufacturer's instructions for the murine C2C12 cell line. Briefly, cells were transfected with 1 mg of luciferase reporter constructs harbouring a consensus NFkB site or CREB binding site and seeded to semi-confluence in 24-well plates. Cells were cotransfected with a b-galactosidase reporter construct (200 ng) containing the constitutively active pPGK promoter to correct for transfection efficiency. Following transfection, cells were differentiated for 5 days. Subsequently, cells were induced with isoproterenol and/or TNF-a for 6 hours. Total lysate was then incubated with luciferase substrate and luminescence was measured on a TopCount luminometer (PerkinElmer Life Sciences, Canberra-Packard, Waverley, UK). Luciferase activity was expressed as fold induction (treated/ untreated) upon normalisation for transfection efficiency.
Isolation of cellular proteins
For preparation of total protein lysates, cells were washed with ice-cold Phosphate Buffered Saline (PBS) and subsequently lysed in RIPA lysis buffer (200 mM NaCl, 50 mM Tris HCl pH 8.0, 0.05% SDS, 2 mM EDTA, 1% NP40, 0.5% Na-Deoxycholate, 2 mM Na 2 MoO 4 and 10 mM NaF, Complete Protease Inhibitor Cocktail (Roche)) or in SDS sample buffer (10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.5% b-mercaptoethanol and Bromophenol Blue).
For isolation of nuclear proteins, cells were washed with PBS, PBS with 2 mM Na 2 MoO 4 and 10 mM NaF and buffer HB (20 mM Hepes pH 7.5, 10 mM NaF, 2 mM Na 2 MoO 4 , 0.2 mM EDTA pH 7.5). After aspiration of the washing buffer, lysis buffer (20 mM Hepes pH 7.5, 10 mM NaF, 2 mM Na 2 MoO 4 , 0.2 mM EDTA pH 7.5, 0.05% NP40, Complete Protease Inhibitor Cocktail (Roche)) was added. Subsequently, cells were scraped and collected. Samples were centrifuged at 17900 g for 1 minute in 4uC. The pellet was recovered and resuspended in Resuspension Buffer (20 mM Hepes pH 7.5, 0.1 mM EDTA pH 7.5, 5 mM NaF, 1 mM Na 2 MoO 4 , 20% glycerol) supplemented with the Complete Protease Inhibitor Cocktail (Roche). Next, equal volume of salt buffer (20 mM Hepes pH 7.5, 1.6 M NaCl, 0.1 mM EDTA pH 7.5, 5 mM NaF, 1 mM Na 2 MoO 4 , 20% glycerol, Complete Protease Inhibitor Cocktail (Roche)) was added. Samples were incubated for 30 minutes in the shaker at 4uC and subsequently centrifuged at 17900 g for 10 minutes at 4uC. Samples were next diluted to equal protein concentration (determined via BioRad protein assay) and 5x concentrated SDS sample buffer was added. The extracts were used subsequently for Western blotting analysis.
Protein contents of RIPA lysates and nuclear extracts were determined using the Bio-Rad protein assay according to manufacturer's instructions. Samples were next diluted to equal protein concentration and 5x concentrated SDS sample buffer was added. The extracts were used subsequently for Western blotting analysis.
Western blotting
10 mg of nuclear proteins, 25 or 50 mg RIPA protein lysates or 25 ml of SDS sample buffer protein lysates were resolved using SDS-PAGE on 10% or 12% polyacrylamide gels, transferred to nitrocellulose membranes (Amersham, Dubendorf, Switzerland) and analysed by Western blotting. Briefly, membranes were incubated with Blocking Buffer (LICOR Biosciences, Lincoln, NE, USA) diluted with PBS in a 1:1 ratio. Subsequently, membranes were probed with primary antibody diluted 1:1000 in Blocking Buffer diluted 1:1 with PBS containing 0.1% Tween (PBS-T). After washing in PBS-T, DyLight secondary antibody (Pierce, Rockford, IL, USA) was applied diluted 1:10000 in Blocking Buffer/PBS-T (1:1). The membranes were then washed in PBS-T and detection was performed using the Odyssey Imaging System (Licor). Subsequently, the membranes were reprobed with Actin, Tubulin, GAPDH, Lamin A/C or PARP antibodies to verify equal loading. Densitometric analysis averaging the results from independent Western blotting experiments was performed using ImageJ.
Chromatin accessibility assay via Real-Time PCR (CHART-PCR)
The nuclease accessibility technique was performed as follows: cells were washed in PBS, scraped and collected by centrifugation at 453 g for 5 minutes at 4uC. Next, cells were resuspended in buffer A (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl 2 , 0.3 M sucrose) and incubated for 10 minutes at 4uC. Next, equal volume of lysis buffer was added (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl 2 , 0.3 M sucrose, 0.4% NP40 and 2 mM Nabutyrate) and cells were incubated for 10 minutes at 4uC. After centrifugation at 240 g for 5 minutes at 4uC, chromatin was resuspended in buffer R (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl 2 , 1 mM Na-butyrate) digested for 30 min at 37uC with restriction enzymes in the buffer recommended by the manufacturer (New England BioLabs). Reactions were terminated by the addition of 26 Proteinase K buffer (100 mM Tris, pH 7.5, 200 mM NaCl, 2 mM EDTA, 1% SDS). Following proteinase K (Qiagen) and RNase A (Qiagen) treatment, genomic DNA (gDNA) was extracted using the phenol/chloroform/isoamyl alcohol (Sigma-Aldrich) method and subsequently resuspended in sterile water after ethanol precipitation. Purified gDNA (10 ng) was used for RT-PCR. Primers were designed to amplify sequences within the murine IL-6 promoter ( 
Chromatin immunoprecipitation (ChIP)
For ChIP experiments, protein/DNA complexes were crosslinked in cellulo by adding formaldehyde directly to the culture medium to a final concentration of 1%. After 10 minutes, glycine was added to a final concentration of 125 mM for another 10 minutes. Cells were washed, scraped and collected. Pellets were lysed in FA lysis buffer (0.1% SDS, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 20 mM Tris pH 8.0) supplemented with Complete Protease Inhibitor Cocktail (Roche). Cells were sonicated using the Diagenode Bioruptor (Liège, Belgium) at high settings (8 min, 30 s on/30 s off, samples cooled on ice and repeat of the 8 minute cycle). Sonicated lysates were mixed in 1:5 ratio with incubation buffer (0.15% SDS, 1% Triton X-100, 150 mM, 1 mM EDTA, 20 mM HEPES-KOH pH 7.5) followed by immunoprecipitation with 5 mg of anti-p65, anti-polymerase RNA II, anti-P-H3 Serine 10, anti-Ac-H3 Lys27, anti-CBP or anti-CREB using Protein A Sepharose 4 Fast Flow beads (Amersham). Samples were decrosslinked overnight at 65uC. All samples were treated with 50 mg/ml of RNase A and 100 mg/ml of Proteinase K. Immunoprecipitated genomic DNA (gDNA) was purified with the QiaQuick PCR purification kit (Qiagen) and subsequently quantified by Real Time PCR using the Roche SYBR Green Mastermix (Roche). Primers used for amplification of the IL-6 promoter and GAPDH control region are listed in Table S1 . 
Medium swap and migration assay
To investigate the influence of myotube-secreted factors on myoblast migration, a medium swap, followed by a migration assay, was performed. Conditioned media were prepared from untreated myotubes or myotubes treated with isoproterenol and/ or TNF-a for 60 minutes. Subsequently, cells were washed twice with DMEM to remove the remaining inducers and incubated with serum-free DMEM for 24 hours to collect conditioned media with secreted factors. Conditioned media were filtered on 0.22 mm pore membranes (MILLEX GS, MF-Millipore MCE Membrane) and applied to myoblasts. As a positive control, IGF-1, dissolved in serum free DMEM, was used. Myoblasts were seeded in GM (20000 cells/well) on a collagen coating (25 mg/mL rat tail monomeric collagen type I; BD Biosciences, Two Oak Park, Bedford, MA, USA) in wells of a 96-well plate. A cell-free area was generated in the middle of the well using stoppers, according to the ORIS cell migration protocol (ORIS; Platypus Technologies). After 5 hours of cell adhesion, stoppers were removed, GM was aspirated, 100 ml of conditioned media was applied and cells were allowed to migrate for 24 hours into the cell-free central zone. Phase-contrast time-lapse movies were recorded for 24 hours with an interval of 10 minutes using a 10x UPlanFL objective (N.A. 0.30) on a CellM system with a IX81 microscope (Olympus). Four to eleven replicates were tested per condition and three independent experiments were performed. The area covered by the cell layer (that increases due to migration towards the central zone) was determined in time using customized software (CELLMIA, unpublished data). Cell migration velocity (mean of n replicates as indicated) is determined based on the slope of linear fit on the area over time data. The relative migration efficiency is the normalized cell velocity over different independent experiments.
Statistical analysis
Statistical analysis was performed using Student's t-test or oneway ANOVA followed by Bonferroni's multiple comparison test with Graphpad Prism 4 software (Graphpad Software Inc.). Migration data are presented as mean 6 standard error and statistical analysis was performed using Wilcoxon pairwise comparison with Bonferroni correction for multiple testing in R version 2.15.2 (The R Foundation for Statistical Computing). Results were considered significant when p-value ,0.05.
Results
C2C12 myotubes express TNF-R1 and b2-ARs
The murine C2C12 cell line is a well-established in vitro model for the study of molecular interactions occurring in skeletal muscle cells at different steps of myogenesis [18, 19] . We first investigated the expression levels of b2-ARs and TNF-R1/2 in undifferentiated myoblasts versus differentiated myotubes. Progression in myogenesis was confirmed by measuring myogenin expression ( Figure  S1A ). We observed that myogenic differentiation was associated with augmented mRNA levels of TNF-R1 as well as b2-AR, as shown in Figure 1A and B, respectively. At the protein level, we did, however, not detect more TNF-R1 in myotubes as compared to myoblasts. Also, we did not detect an increase in the immunoreactive signal representing the monomeric b2-AR, which has a molecular weight of approximately 50 kDa. We did however observe that multiple high-molecular weight immunoreactive bands appear upon myogenic differentiation of C2C12 cells ( Figure 1B ). To corroborate that the high-molecular weight immunoreactivities indeed represent b2-ARs, we overexpressed a hemagglutinin (HA)-tagged b2-AR (b2-AR-HA) in HEK-293T cells, which do not express endogenous b2-AR. Like in C2C12 cells, we found higher molecular weight bands that react with the anti-b2-AR antibody. In addition, we found that these bands overlap with immunoreactivities detected with anti-HA, indicating they indeed derive from b2-AR species, and probably represent post-translationally modified or oligomeric forms of the b2-AR ( Figure S1B ) [20, 21] . In conclusion, these data indicate C2C12 myotubes express both TNF-R1 and b2-AR protein and indicate the expression of variant b2-AR species is upregulated in the course of myogenesis. Given that myotubes have been shown to secrete a wide variety of mediators when subjected to proinflammatory stimuli [22] , and as C2C12 myotubes express both TNF-R1 and b2-AR2, we have used C2C12 myotubes for further experiments into b2-AR2/TNF-R1 crosstalk.
Effect of b-agonist cotreatment on TNF-a-induced, NFkB-dependent, inflammatory gene expression in skeletal muscle cells
In physiological and pathological circumstances, such as during an acute boost of exercise or in chronic inflammatory disease, skeletal muscle cells express a number of NF-kB-dependent cytokines and other inflammatory markers [1, 23] . Here, we performed a RT-qPCR analysis to assess how b-agonist cotreatment modulates the expression of well-known NF-kB target genes with a previously demonstrated role in skeletal muscle homeostasis [15, 23, 24] . The presence of NF-kB binding sites in the promoters of the selected genes was confirmed by a bioinformatics analysis using P-Scan (Table S2) . For each gene, the promoter region of 500 bp upstream to the Transcription Starting Site was investigated with the Transcription Factor Binding Sites matrices available in the TRANSFAC databases.
We found that in C2C12 myotubes, TNF-a significantly induced the expression of intercellular adhesion molecule 1 (ICAM-1), NF-kB inhibitor alpha (IkBa), chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-C motif) ligand 5 (CCL5), whereas it had modest yet insignificant effects on the expression of interleukin-6 (IL-6) and chemokine (C-X-C motif) ligand 5 (CXCL5) (Figure 2 ). We found no clear effects of TNF-a on the expression of interleukin-7 (IL-7), interleukin-15 (IL-15) and Brain derived neurotrophic factor (BDNF) ( Figure S2 ). Isoproterenol by itself did not significantly affect the expression of any of the investigated genes, but had a mild positive effect on the expression of CXCL5 and IL-6. Interestingly, we found that isoproterenol cotreatment did not significantly modulate TNF-a-induced CCL5 and IkBa transcription ( Figure 2D, F) , but enhanced the effect of TNF-a on the expression of CCL2 and ICAM-1 ( Figure 2C , E) and induced a pronounced synergy for IL-6 and CXCL5 ( Figure 2A , B, Table 1 ). Overall, the effect of TNF-a on the expression of the selected genes was rapid and transient, peaking after 2 hours of treatment and then rapidly declining, and these kinetics were not modulated by isoproterenol cotreatment. Only CCL5 mRNA levels peaked at 5 hours, both upon TNF-a and TNF-a and isoproterenol cotreatment, and were maintained even after 16 hours induction (Figure 2 D) . We concluded that in C2C12 myotubes a subset of NF-kB-dependent genes exists with different responses to TNF-a or costimulation with isoproterenol.
Cytoplasmic signalling crosstalk upon b 2 -AR/TNF-R coactivation in C2C12 myotubes
Because isoproterenol enhanced the expression of several typical NF-kB target genes, we explored what could be the molecular basis of these effects. Upon binding to its receptor(s), TNF-a triggers the canonical NF-kB cascade, initiated by IKKb activation, IkBa degradation, phosphorylation of the NF-kB p65 subunit on serine 536 and its subsequent translocation from the cytoplasm to the nucleus [4] . As evaluated by Western blotting, we detected canonical NF-kB activation in C2C12 myotubes treated with TNF-a. We observed rapid phosphorylation of p65 on serine 536, degradation of IkBa (Figure 3 A) , and nuclear translocation of p65 ( Figure 3B ). In line with this, TNF-a also induced an NFkB reporter gene transiently transfected in C2C12 cells ( Figure 3C ). Isoproterenol treatment by itself had no effect on any of these aspects of canonical NF-kB activation and did not modulate the effects of TNF-a ( Figure 3A-C) .
In addition to the NF-kB pathway, TNF-a triggers activation of Mitogen Activated Protein Kinases (MAPKs) and Mitogen and Stress-activated Kinase 1 (MSK-1) which cooperate with NF-kB in driving inflammation [17, 25] . We found that in C2C12 myotubes, TNF-a activated JNK (Jun N-terminal kinase), ERK (Extracellular signal-regulated kinase) and p38 MAPKs and MSK-1 ( Figure 3D -G). Isoproterenol by itself did not have significant effects on the phosphorylation of any of the MAPKs or MSK-1. Isoproterenol slightly inhibited TNF-a-induced phosphorylation of ERK, JNK and MSK-1, whereas it did not significantly affect TNF-a-induced p38 MAPK activation ( Figure 3D-G) . Collectively, this suggests that the potentiation of TNF-a-induced gene expression by isoproterenol is unlikely to be mediated by cytoplasmic modulation of NF-kB activity (Figure 2) .
The canonical signalling pathway that is induced by b 2 -AR triggering is the protein kinase A (PKA)/ cAMP-response elementbinding protein (CREB) cascade. We detected rapid phosphorylation of CREB on serine 133 in cells treated with isoproterenol as well as TNF-a. Combined treatment did not further potentiate CREB phosphorylation ( Figure 4A ). Nuclear translocation of the PKA catalytic subunit (PKAc) was only detected in cells treated with isoproterenol and not in TNF-a-treated cells ( Figure 4B ). Whereas both TNF-a and isoproterenol induced CREB phosphorylation, only isoproterenol-activated CREB was able to induce a CRE reporter gene in C2C12 cells ( Figure 4C ). TNF-a cotreatment did not modulate isoproterenol-induced CRE activity.
b 2 -AR/TNF-R cotreatment induces chromatin modifications required for efficient recruitment of NF-kB Because we did not detect any cytoplasmic b 2 -AR/TNF-Rs crosstalk events that could explain the observed synergy, we next explored nuclear crosstalk. We used the IL-6 gene, a prototypical NF-kB target gene, with known function in skeletal muscle, and the most potently affected gene in our RT-qPCR analysis, as a model system. The IL-6 gene has a complex promoter architecture and, among others, contains functional transcription factor binding sites for NF-kB and CREB [17, 26] .
The accessibility of a gene's promoter to transcription factors is reflected in its susceptibility to nuclease digestion. In CHART-PCR, this feature is exploited and the accessibility of a selected DNA sequence is determined by digesting chromatin using nucleases and then quantifying the amount of remaining uncut gDNA in the digested chromatin sample via qPCR. Here, we digested the proximal IL-6 gene promoter using two restriction enzymes (AatII, HincII) that cut in the proximal IL-6 promoter, in the vicinity of CREB and NF-kB binding sites respectively. Then, we amplified the sequence of interest via qPCR, using primers that recognise the sequence flanking the restriction enzyme recognition sites ( Figure 5A ). Results were normalised as explained in the Materials and Methods section and expressed as chromatin opening. We found that the IL-6 promoter is susceptible to digestion with the AatII and HincII restriction enzymes, only upon cotreatment with TNF-a and isoproterenol ( Figure 5B ). As expected, no chromatin opening was apparent, at an irrelevant region (not containing restriction sites for AatII and HincII) of the IL-6 gene ( Figure 5B ).
Covalent modification of histone tails is a crucial event in the regulation of chromatin dynamics. In particular enhanced acetylation of histone H3 has been detected at transcriptionally active chromatin [27] . To investigate whether histone acetylation is implicated in IL-6 transcription induced by TNF-a/isoproterenol cotreatment, we first explored how the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) affects IL-6 transcription. Remarkably, we found that TSA, at subcytotoxic dose (100 nM), almost completely abrogated IL-6 transcription triggered by isoproterenol, TNF-a or the combination of both, indicating IL-6 transcription is inhibited, rather than enhanced by histone acetylation ( Figure 5C ). To assess histone H3 acetylation at the IL-6 promoter, we performed ChIP using an antibody recognising histone H3 acetylated at the Lys 27 residue, a modification for which the association with transcriptional activation is well established [28] [29] [30] . We found that, at the IL-6 promoter, histone H3 carried a constitutive acetylation mark at Lys 27, that was not significantly enhanced upon isoproterenol and/or TNF-a treatment ( Figure S3A ). We also failed to detect enhanced histone H3 acetylation using a pan acetyl-histone-H3 antibody (data not shown). The efficiency of the dose of TSA that we used to promote histone acetylation was confirmed by the detection of histone H3 Lys 27 acetylation in TSA-treated C2C12 cells by confocal microscopy ( Figure S3B ).
We found that isoproterenol stimulated PKA nuclear entry in C2C12 cells, while TNF-a promoted phosphorylation of MSK-1. Intriguingly, both PKA and MSK-1 have been shown to trigger phosphorylation of histone H3 on serine 10, a modification associated with chromatin relaxation and transcriptional activity [31, 32] . Via ChIP analysis, we detected very modest histone H3 phosphorylation at the IL-6 promoter upon isoproterenol stimulation that was significantly potentiated upon cotreatment of C2C12 cells with TNF-a ( Figure 5D ). Finally, we observed that isoproterenol promoted recruitment of CREB, CREB-binding protein (CBP) and RNA polymerase II to the IL-6 promoter, whereas TNF-a induced recruitment of NF-kB p65. Combined treatment with TNF-a and isoproterenol moreover potentiated the recruitment of p65, CBP and RNA polymerase II to the IL-6 promoter ( Figure 5E-H) . Isoproterenol-induced CREB recruitment was not modulated by TNF-a cotreatment. The specificity of the observed responses is indicated by the fact that we did not detect any of the observed responses at an irrelevant housekeeping gene (GAPDH) or using aspecific antibodies or beads only for the immunoprecipitation ( Figure S3A, C-H) . These results show that only combined stimulation with TNF-a and isoproterenol leads to chromatin remodelling at the IL-6 promoter.
Myotube-derived cytokines induce migration of myoblasts
Recent literature shows that, upon contraction or inflammation, skeletal muscle cells express several cytokines with chemotactic properties [24, 33] . Because we observed that cotreatment of C2C12 myotubes with isoproterenol enhanced transcription of several TNF-a-induced cyto-/chemokines that are known to modulate the migratory properties of cells, we investigated whether these factors induced migration of undifferentiated C2C12 myoblasts. It was reported that C2C12 myoblasts exhibit spontaneous mobility, which can be further stimulated by IGF-1 [33] . To analyse whether TNF-a/isoproterenol cotreatment induces the production of chemotactic factors by myotubes, we performed migration assays using myoblasts treated with myotubeconditioned medium. IGF-1 stimulation was used as a positive control. As shown in Figure 6 and Figure S4 , myoblast cells treated with conditioned medium from myotubes stimulated with only TNF-a or isoproterenol displayed a modest, albeit significant increase in myoblast migration efficiency compared to the control condition. Importantly, myoblasts treated with conditioned medium derived from myotubes, which were stimulated with the combination of TNF-a and isoproterenol, migrated significantly faster than those treated with conditioned medium from myotubes treated with only TNF-a or isoproterenol ( Figure 6C , Figure S4 ). This indicates that the conditioned medium of the cotreated myotubes has a stronger chemotactic potential on undifferentiated myoblasts.
Discussion
The devastating role of TNF-a and NF-kB in skeletal muscle inflammation and atrophy is well documented [2, 5] . Here, we investigated whether and how b-agonists, that are known for their anabolic and anti-inflammatory properties, modulate the effects of TNF-a on the expression of inflammatory factors in skeletal muscle cells. We used the murine C2C12 cell line as in vitro model system and found that the expression of b 2 -ARs was much more prominent, both at the mRNA and protein level, in differentiated myotubes as compared to undifferentiated myoblasts, indicating myotubes would be more susceptible to regulation by b 2 -AR-agonists. In agreement with this finding, elevated expression of the b 2 -AR was reported in regenerating myofibers after injury [7] . Whereas we also observed increased TNF-R1 expression at the mRNA level, this was not reflected at the protein level. Enhanced TNF-R1 mRNA levels were previously reported in regenerating myofibers, but the level of protein in the latter study was not investigated [34] . In another study decreased activation of NF-kB upon TNF-a treatment was observed upon myogenesis [35] , but in this study TNF-R1 expression levels were not investigated and the diminished response could also be due to post-receptor regulatory mechanisms [36] . Our data suggest that in C2C12 cells TNF-R1 protein levels are not regulated upon myogenic differentiation, despite clear differences in mRNA levels. The reason for this discrepancy remains to be elucidated, but probably depends on post-transcriptional regulation of TNF-R1 expression.
Several proinflammatory mediators are upregulated in myotubes upon TNF-a challenge [15, 24] and in muscle wasting disorders [24, 37] . In line with this, we found a significant increase in the expression of selected NF-kB-dependent target genes in C2C12 cells treated with TNF-a. Interestingly, we observed that isoproterenol treatment by itself did not significantly affect the expression of these genes, but potently enhanced TNF-a-induced expression of a subset of inflammatory factors, such as IL-6 and CXCL5, and to a lesser extent that of CCL2 and ICAM-1, whereas that of others (CCL5 and IkBa) remained unaffected. The regulation of IL-6 expression was investigated previously in C2C12 cells stimulated with lipopolysaccharide (LPS) and epinephrine [13] . Similar to what we observe here using TNF-a as a proinflammatory stimulus, the authors reported synergistic IL-6 expression upon LPS/epinephrine cotreatment, indicating the synergy depends on a signalling protein that is common to TNF-R and Toll-like receptor (TLR) pathways. As opposed to previous reports of anti-inflammatory effects of b-agonists [10-12], we did not find any evidence for that in C2C12 cells. The antiinflammatory effects of b-agonists have been mostly explained by b 2 -AR-mediated upregulation of IkBa levels, either via induction of its transcription, or by promoting its stability through interaction with the GPCR adaptor b-arrestin [10, 12, 38] . In C2C12 cells, we and others [13] did not detect any modulation of IkBa mRNA or protein levels, indicating b 2-AR-dependent regulation of IkBa levels is a cell type-specific process. The lack of effects on IkBa expression was confirmed by our observation that isoproterenol cotreatment did not hamper nuclear translocation of NF-kB p65. In addition, we did not find potentiation of TNF-a-induced MAPKs or MSK-1 activation by isoproterenol, rather we found mild inhibition of MSK-1, ERK and JNKindicating the effect of isoproterenol cannot be explained by cytoplasmic crosstalk with canonical TNF-a-induced signalling cascades. Whereas Frost et al. [13] suggested that epinephrine promotes activation of ERK, p38 and JNK MAPKs, we did not find any evidence for that using isoproterenol as a stimulus. Activation of these MAPKs by epinephrine in the publication by Frost et al. was however solely supported by effects of pharmacological inhibitors on IL-6 expression.
The most important novel finding in this paper is the observation that, in addition to IL-6, the expression of several chemokine genes is potentiated upon TNF-a/isoproterenol cotreatment of skeletal muscle cells. The genes we investigated in this study all contain NF-kB responsive elements in their proximal promoters. As is evident from Table S2 , there is significant variation in the sequences of these elements. Although the investigated selection of genes is too small to make any reliable predictions, it is noteworthy that the NF-kB consensus sequences in the most responsive IL-6 (GGGATTTTCC) and CXCL5 (GGGAATTTCC) promoters bear the strongest similarity among the investigated genes. Recently, Siggers et al. [39] performed a comprehensive in vitro analysis of DNA binding by NF-kB dimers.
Using Siggers' open source dataset, we evaluated whether the IL-6 and CXCL5 NF-kB sequences showed a particular preference for selected NF-kB dimers, as compared to genes that were not prone to TNF-a/isoproterenol coregulation, but could not find evidence for that. In fact, the binding preference of the NF-kB sequence in the IL-6 promoter resembled most that of the kB sequence in the IkBa promoter, which was not susceptible to synergistic regulation by TNF-a/isoproterenol. Evaluating whether the sequence of the NF-kB responsive element determining for the response to isoproterenol will however require more extensive, genome-wide, analysis. In addition to specifying NF-kB dimer binding, the sequence of the kB site also dictates which co-activators will bind to a selected promoter, and accumulating evidence suggests NFkB dimers can adopt different conformations when bound to different DNA sequences [40] . In line with this, even a single nucleotide change within a kB sequence was shown to affect cofactor specificity of NF-kB dimers [41] . Cofactor specificity is also determined by post-translational modifications of NF-kB family members. Interestingly, both PKA and MSK-1 have been shown to phosphorylate p65 on its serine 276 residue, which promotes its association with the CBP coactivator and selective NF-kB dependent gene induction [42, 43] . Because of the lack of specific antibodies recognizing p65 phosphorylated at the serine 276 residue, we were unable to investigate whether this phosphorylation is triggered in C2C12 cells upon activation of PKA and/or MSK-1 [44] . We recently also reported synergistic IL-6 expression in human 1321N1 astrocytes cotreated with TNFa/isoproterenol [26] indicating the TNF-R1/b 2 -AR synergy is not a phenomenon restricted to C2C12 cells. Nevertheless, in astrocytes we also detected inhibitory effects of isoproterenol (for instance at the ICAM-1 gene), whereas in the current study isoproterenol did not block the expression of any of the investigated genes (including ICAM-1). Our results indicate that the effects of isoproterenol are not only gene-selective, with only a selection of NF-kB dependent genes being susceptible to potentiation by isoproterenol, but that there is also an important cell type-specific component determining the outcome of TNF-R1/b 2 -AR co-activation. This cell-type specificity is supported by other reports describing different effects of b-agonists on the expression of selected inflammatory mediators, depending on the cell type investigated [11, 45, 46] .
Expression of NF-kB target genes is regulated at multiple levels and selectivity is accomplished, among others, by co-operation of multiple transcription factors and cofactors in so-called enhanceosome structures as well as by epigenetic mechanisms [47] . We showed via chromatin accessibility assays that b 2 -AR/TNF-R coactivation induces chromatin remodelling at the IL-6 promoter. Both MSK-1 and PKA can directly phosphorylate histone H3 and recruit chromatin-remodelling complexes leading to increased promoter accessibility [31, 32, 48] . In agreement with this, we observed that in C2C12 cells concurrent activation of MSK-1 and PKA is associated with enhanced histone H3 phosphorylation and chromatin relaxation at the IL-6 promoter. Whereas we cannot exclude that there are also effects of the individual triggers (as is indicated by detectable recruitment of p65, CREB, CBP and RNA polymerase II also upon stimulation of cells with only isoproterenol or TNF-a) that are below the detection limit of our assays, it is clear that b 2 -AR/TNF-R co-activation promotes transcriptional synergy.
Intriguingly, it was reported that at the c-fos promoter (in vitro) CREB binding and phosphorylation are required to recruit MSK-1, which then phosphorylates histone H3 [49] . Here, we observed that, although both TNF-a and isoproterenol stimulate phosphorylation of CREB on serine 133, CREB activation is only promoted in the presence of isoproterenol. These results are in agreement with previous reports demonstrating that both MSK-1 and PKC phosphorylate CREB on serine 133 to a similar extent as PKA, but that only PKA-mediated phosphorylation resulted in CREBdependent transcription [50, 51] . According to the generally accepted model for CREB-dependent transcriptional activation, CREB is constitutively bound to its target gene promoters and transcriptional activation requires phosphorylation of CREB. We have attempted to immunoprecipitate phosphorylated CREB from the IL-6 promoter using two antibodies that recognise CREB phosphorylated at serine 133, but failed to recover it (data not shown). Instead, we found that CREB was actively recruited to the IL-6 promoter upon isoproterenol, but not upon TNF-a treatment. We previously reported CREB recruitment at the IL-6 promoter upon TNF/isoproterenol cotreatment in human astrocytes [26] . These findings are moreover in line with other reports demonstrating active CREB recruitment at selected gene promoters. For instance, it has been shown that CREB recruitment occurs at glucagon-responsive gene promoters in hepatocytes treated with forskolin [52] , at the c-fos promoter in neurons treated with BDNF [53] and at the ICER promoter in forskolin-treated PC12 cells [54] .
We found that TNF-a induced CREB phosphorylation, but did not promote activation of a CREB-dependent reporter gene and did not induce CREB recruitment to the IL-6 promoter. It is, however, possible that TNF-a-induced CREB phosphorylation plays a role in the transcriptional activation of other genes, perhaps requiring different CREB co-activators. Evaluating the contribution of TNF-a induced MSK-1 versus isoproterenol-induced PKA in CREB-mediated gene transcription will, however, require further study.
In addition to phosphorylation, acetylation of histones plays a crucial role in gene expression [27, 28] . Moreover, combinations of multiple histone modifications can reinforce the robustness of the chromatin state and as a consequence modulate gene expression [55, 56] . We previously proposed that the selective synergy at the IL-6 promoter in astrocytes was the result of co-operative recruitment of the transcriptional coactivator CBP by CREB and NF-kB, that are positioned in close proximity at the IL-6 promoter [26] . Interestingly, also the CXCL5 promoter contains a CREB and NF-kB element in its proximal promoter, indicating this could be a signature of genes susceptible to TNF-R1/b 2 -AR co-activation. CBP acts as a transcriptional coactivator by either acetylating histone tails via its intrinsic acetyl-transferase activity or by recruiting additional histone acetyl-transferases (HATs), hence promoting chromatin accessibility [57, 58] . Surprisingly, whereas CBP is efficiently recruited to the IL-6 promoter upon TNF-a/ isoproterenol cotreatment in the present study, we did not find evidence for a positive role of histone acetylation in promoting chromatin relaxation. This observation is in line with a previous report showing reduced IL-6 expression in C2C12 cells treated with TSA [13] and suggests the existence of cell-type specific epigenetic regulatory mechanisms acting at the IL-6 promoter. Importantly, whereas previous studies show coupling of histone H3 phosphorylation and acetylation as prerequisite for transcriptional activation [59, 60] , we could not find evidence for that in our model system. It could be that, at the IL-6 promoter, CBP has a function independent of its HAT activity. It is indeed well known that CBP can acetylate non-histone proteins and in this way affect transcriptional activity. For instance, it has been shown that CBP acetylates CREB [61] and NF-kB p65 [62, 63] , and that these modifications are instrumental for efficient transcriptional activation. Further experiments will however be required to investigate whether this indeed occurs at the IL-6 promoter.
In conclusion, the most striking observation of this study is that co-activation of the TNF-R1 and b 2 -AR potently enhances the expression of a subset of inflammatory mediators in C2C12 skeletal muscle cells. Recent reports demonstrated that IL-6, as well as C-C and C-X-C chemokines, regulate various stages of skeletal muscle regeneration [33, 64, 65] . For example, IL-6, CXCL5, CCL2 and CCL5 were shown to induce leukocyte influx to remove damaged myofibers [24, 65] and stimulate myoblast migration to fill in damaged areas [33, 64, 66] . Here, we show that cotreatment of myotubes with TNF-a and isoproterenol synergistically promotes the secretion of factors that induce the migration of undifferentiated myoblasts in vitro. In future studies, it would be interesting to investigate how this affects the recruitment of satellite cells and leukocytes in vivo, and in particular in models of TNF-adependent muscle disease.
Based on our findings, we propose the following model ( Figure 7 ): in C2C12 myotubes (I) TNF-R activation promotes activation of the canonical NF-kB signalling cascade and MAPKs, including the downstream p38 MAPK target MSK-1, which can phosphorylate CREB (II) b 2 -AR activation is associated with activation of PKA, which is the canonical CREB kinase (III) b 2 -AR activation does not interfere with early events in TNFtriggered pro-inflammatory NF-kB and MAPK activation (IV) b 2 -AR/TNF-R coactivation is associated with enhanced phosphorylation of histone H3 and chromatin relaxation at selected gene promoters (i.e. IL-6) and this is paralleled by recruitment of CREB, NF-kB p65 and CBP transcriptional coactivators as well as RNA polymerase II (V) TNF-R/b 2 -AR coactivation leads to synergistic gene expression of selected pro-inflammatory mediators and the secretion of factors that promote the migration of undifferentiated myoblasts.
Finally, as we did not detect anti-inflammatory effects of bagonists in C2C12 skeletal muscle cells, but instead potentiation of TNF-a action, we suggest caution in the proposed use of bagonists as therapeutic agents for inflammatory myopathies and urge for further study. 
Supporting Information
